|Bid||19.25 x 3100|
|Ask||21.05 x 1300|
|Day's range||19.89 - 21.02|
|52-week range||17.11 - 37.75|
|Beta (3Y monthly)||1.77|
|PE ratio (TTM)||N/A|
|Earnings date||12 Feb 2020 - 17 Feb 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||25.08|
IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.
Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.
Biogen Inc. (BIIB) and Alkermes plc (ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Biogen holds the exclusive, worldwide license to commercialize VUMERITY and intends to make it available in the United States in the near future. “The FDA’s approval of VUMERITY delivers on Biogen’s commitment to pursue new therapies that may provide meaningful impact for people living with relapsing MS, and we look forward to bringing it to the MS community as an additional treatment option,” said Alfred Sandrock, Jr., M.D., Ph.D., executive vice president, research and development, and chief medical officer at Biogen.
Alkermes (ALKS) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Alkermes (ALKS) delivered earnings and revenue surprises of 80.00% and 1.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.
Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.
Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex